New angiogenesis research reported from St. Michael's Hospital, Division of Cardiology

Current study results from the report, "Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: a phase 2 randomized, controlled trial of AdVEGF(121) (AdVEGF121) versus maximum medical treatment," have been published. According to a study from Toronto, Canada, "The demonstration that angiogenic growth factors can stimulate new blood vessel growth and restore perfusion in animal models of myocardial ischemia has led to the development of strategies designed for the local production of angiogenic growth factors in patients who are not candidates for conventional revascularization. The results of recent clinical trials of proangiogenesis gene therapy have been...

Want to see the full article?

• Purchase this article for only $3.00